Theriva Biologics TOVX Income Statement (2010-2026)

NYSE TOVX
$0.24 +0.01 (+4.35%)
At close: Aug 20, 2026 · 4:00 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
0.53M0.53M0.63M0.63M0.63M0.63M0.63M0.71M0.71M0.71M0.71M0.92M1.13M1.35M2.81M6.75M10.33M12.14M45.92M45.92M
Revenue & cost
Revenue (Quarter)
0.30M
Operating items
Research & Development (Quarter)
1.97M2.78M2.60M3.48M2.57M3.07M2.98M3.13M4.01M4.20M3.46M2.95M2.73M2.89M2.97M1.95M2.55M1.13M0.35M1.27M
Selling, General & Administrative (Quarter)
1.30M2.49M1.66M1.54M2.42M4.25M2.20M2.69M0.21M2.02M1.93M1.47M2.30M1.69M1.45M11.18M1.89M0.93M2.07M2.03M
Other Operating Expenses (Quarter)
4.07M2.85M
Operating Expenses (Quarter)
3.27M5.26M4.25M5.03M4.99M7.32M5.18M5.82M4.22M6.22M5.39M8.49M7.89M4.58M4.42M13.13M4.44M2.06M2.43M3.29M
Operating Income (Quarter)
-3.27M-5.26M-4.25M-5.03M-4.99M-7.32M-5.18M-5.82M-4.22M-6.22M-5.39M-8.49M-7.89M-4.58M-4.42M-13.13M-4.44M-2.06M-2.13M-3.29M
EBIT (Quarter)
-3.27M-5.26M-4.25M-5.03M-4.99M-7.32M-5.18M-5.82M-4.22M-6.22M-5.39M-8.49M-7.89M-4.58M-4.42M-13.13M-4.44M-2.06M-2.13M-3.29M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.00M0.00M0.03M0.17M0.32M0.36M0.38M0.38M0.31M0.23M0.17M0.16M0.14M0.10M0.05M0.07M0.07M0.08M0.08M
Other Non Operating Income (Quarter)
-0.02M-0.01M-0.01M-0.19M0.01M-0.00M0.01M-0.46M-0.00M-0.00M0.00M-0.72M-0.00M0.02M0.01M-0.01M0.00M-0.00M
Non Operating Income (Quarter)
0.00M0.00M-0.02M0.02M0.16M0.31M0.37M0.38M0.39M0.31M0.23M0.17M0.16M0.13M0.09M0.07M0.08M0.07M0.08M0.08M
Net income details
EBT (Quarter)
-3.41M-5.34M-4.27M-5.01M-4.83M-7.00M-4.81M-5.44M-3.83M-5.91M-5.17M-8.32M-7.73M-4.45M-4.32M-13.06M-4.36M-2.00M-2.04M-3.22M
Tax Provisions (Quarter)
-0.53M-0.34M0.87M-0.33M-0.36M-0.53M0.68M
Profit After Tax (Quarter)
-3.27M-5.26M-4.27M-4.48M-4.49M-6.45M-4.48M-5.08M-3.30M-5.49M-5.17M-8.32M-7.73M-4.49M-4.32M-13.06M-4.36M-3.94M-2.04M-3.22M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)
-3.41M-5.34M-4.27M-4.48M-4.49M-7.87M-4.48M-5.08M-3.30M-6.59M-5.17M-8.32M-7.73M-4.45M-4.32M-13.06M-4.36M-2.00M-2.04M-3.22M
Consolidated Net Income (Quarter)
-3.41M-5.34M-4.27M-4.48M-4.49M-7.87M-4.48M-5.08M-3.30M-6.59M-5.17M-8.32M-7.73M-4.45M-4.32M-13.06M-4.36M-2.00M-2.04M-3.22M
Income towards Parent Company (Quarter)
-3.41M-5.34M-4.27M-4.48M-4.49M-7.87M-4.48M-5.08M-3.30M-6.59M-5.17M-8.32M-7.73M-4.45M-4.32M-13.06M-4.36M-2.00M-2.04M-3.22M
Preferred Dividend Payments (Quarter)
-1.47M
Net Income towards Common Stockholders (Quarter)
-3.30M-5.29M-4.27M-4.48M-4.83M-6.42M-4.48M-5.10M-3.30M-5.45M-5.20M-8.32M-7.70M-4.45M-4.32M-13.10M-4.40M-3.55M-2.04M-3.22M
Additional items
EPS (Basic) (Quarter)
-6.25-10.85-7.73-7.06-7.62-10.48-7.40-8.41-4.84-8.46-7.58-10.72-6.79-3.30-1.55-1.94-0.45-0.29-0.05-0.07
EPS (Diluted) (Quarter)
-6.25-10.85-7.73-7.06-7.62-10.48-7.40-8.41-4.84-8.46-7.58-10.72-6.79-3.30-1.55-1.94-0.45-0.29-0.05-0.07
Shares Outstanding (Quarter)
0.53M0.49M0.55M0.63M0.63M0.61M0.60M0.61M0.68M0.64M0.69M0.78M1.13M1.35M2.78M6.75M9.68M12.14M41.07M45.89M
Shares Outstanding (Diluted) (Quarter)
0.53M0.49M0.55M0.63M0.63M0.61M0.60M0.61M0.68M0.64M0.69M0.78M1.13M1.35M2.78M6.75M9.68M12.14M41.07M45.89M
EBITDA (Quarter)
-3.27M-5.26M-4.25M-5.03M-4.99M-7.32M-5.18M-5.82M-4.22M-6.22M-5.39M-8.49M-7.89M-4.58M-4.42M-13.13M-4.44M-2.06M-2.13M-3.29M
Interest Expenses (Quarter)
0.14M0.08M0.11M0.35M0.14M0.67M0.72M2.43M28.35M2.13M1.96M1.80M0.01M0.17M1.31M0.10M0.97M0.68M2.54M
Tax Rate (Quarter)
10.626.94-12.416.866.6013.76-11.58